Sol-gel and beimei pharma announce an asset purchase agreement to commercialize twyneo® in the mainland of china, hong kong, macau, taiwan and israel

Ness ziona, israel, may 16, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%) for gorlin syndrome, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that it has signed an asset purchase agreement with chinese based shenzhen beimei pharmaceutical co. ltd, for the commercialization of twyneo, for the treatment of acne vulgaris, in the mainland of china, hong kong, macau, taiwan and israel.
SLGL Ratings Summary
SLGL Quant Ranking